Dechra Pharmaceuticals PLC Trading Update and Notice of Preliminary Results (8339E)
12 Julio 2021 - 01:00AM
UK Regulatory
TIDMDPH
RNS Number : 8339E
Dechra Pharmaceuticals PLC
12 July 2021
Monday, 12 July 2021
Dechra(R) Pharmaceuticals PLC
(Dechra, Group, Company)
Trading Update
The Board of Dechra issues the following unaudited Trading
Update covering the Group's financial year ended 30 June 2021 (the
Period) ahead of the announcement of its Preliminary Results.
Overview
The Board is pleased to report that the stronger than expected
trading performance as outlined in our recent Trading Update on 8
June 2021 continued for the remainder of the Period as anticipated.
The Group delivered excellent year on year organic revenue growth
supplemented by the product acquisitions of Osurnia(R) and
Mirataz(R) both of which delivered good incremental growth.
Highlights
* Reported Group revenue for the Period increased by
c.21% at constant exchange rate (CER) (c.18% at
actual exchange rate (AER))
* European Pharmaceuticals revenue growth was c.20% at
CER (AER c.20%)
* North America Pharmaceuticals revenue growth was
c.22% at CER (AER c.14%)
* Mirataz launched in Europe and globally performing
strongly and ahead of expectations
* Eleven months of strong contribution from Osurnia
Ian Page, Chief Executive Officer, said:
"We are pleased to have continued to outperform a robust market
throughout the pandemic affected financial year. We have benefited
from above average market growth in the majority of our key CAP
markets. The reasons for this growth are not yet fully clear with
evidence of increased companion animal numbers remaining
unconfirmed at this point. What is clear is that people have been
spending more time with their pets and have therefore been more
cognitive of their welfare. Thanks to the exceptional effort of our
talented people our business has operated well throughout the
pandemic; all Manufacturing sites and laboratories have remained
operational and communication with customers has been excellent
through increased use of digital media."
Operational Review
European Pharmaceuticals
In the Period, our total European Pharmaceuticals Segment
revenue increased by c.20% at CER (AER c.20%), including the
acquisitions of Osurnia (acquired 28 July 2020) and launch of
Mirataz (launched February 2021).
Existing revenue, excluding third party contract manufacturing
(non-animal health which Dechra is strategically exiting),
increased by c.16% at CER (AER c.16%).
North American Pharmaceuticals
In the Period, our total North American Segment revenue
increased by c.22% at CER (AER c.14%) including the acquisitions of
Ampharmco (acquired 28 August 2019) and Mirataz (acquired 16 April
2020) and Osurnia.
Excluding acquisitions existing net revenues increased by c.16%
at CER (AER c.9%).
Notice of Results
Dechra will announce its Preliminary Results for the Period on
Monday, 6 September 2021.
Enquiries:
Dechra Pharmaceuticals PLC
Ian Page, Chief Executive Officer Office: +44 (0) 1606
814 730
Paul Sandland, Chief Financial Officer Office: +44 (0) 1606
email : corporate.enquiries@dechra.com 814 730
TooleyStreet Communications Ltd
Fiona Tooley, Director Mobile: +44 (0) 7785
email: fiona@tooleystreet.com 703 523
Office: +44 (0) 121
309 0099
Notes:
1) Foreign Exchange Rates:
FY2021 Average: EUR 1.1287: GBP 1.0; USD 1.3466: GBP 1.0
FY2021 Closing: EUR 1.1654: GBP 1.0; USD 1.3850: GBP 1.0
FY2020 Average: EUR 1.1396: GBP 1.0; USD 1.2601: GBP 1.0
FY2020 Closing: EUR 1.0960: GBP 1.0; USD 1.2273: GBP 1.0
2) Acquisitions:
August 2019: Ampharmco, LLC (Ampharmco)
April 2020: Mirataz product rights
July 2020: Osurnia product rights
About Dechra
Dechra is a global specialist veterinary pharmaceuticals and
related products business. Our expertise is in the development,
manufacture and sales and marketing of high quality products
exclusively for veterinarians worldwide. Dechra's business is
unique as the majority of its products are used to treat medical
conditions for which there is no other effective solution or have a
clinical or dosing advantage over competitor products.
For more information, please visit: www.dechra.com
Stock Code: Full Listing (Pharmaceuticals): DPH
LEI: 213800J4UVB5OWG8VX82
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of
Dechra Pharmaceuticals PLC.
Forward Looking Statement
This document may contain certain forward-looking statements.
The forward-looking statements reflect the knowledge and
information available to the Company during the preparation and up
to the publication of this document. By their very nature, these
statements depend upon circumstances and relate to events that may
occur in the future thereby involve a degree of uncertainty.
Therefore, nothing in this document should be construed as a profit
forecast by the Company.
Market Abuse Regulation (MAR)
The information contained within this announcement may
constitute inside information stipulated under the Market Abuse
Regulation (EU) No. 596/2014. Upon the publication of this
announcement via the Regulatory Information Service, this inside
information is now considered to be in the public domain.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TSTFFFEIDRIILIL
(END) Dow Jones Newswires
July 12, 2021 02:00 ET (06:00 GMT)
Dechra Pharmaceuticals (LSE:DPH)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Dechra Pharmaceuticals (LSE:DPH)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024